Red-flag symptoms of hATTR amyloidosis

Learn about how to recognize the signs in your patients

What is hATTR amyloidosis?

Facts about the disease

Sign up to receive updates

Stay up-to-date on news about hATTR amyloidosis

References:

Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50-57.
Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675-682.
Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122lle hereditary transthyretin amyloidosis J Cardiovasc Transl Res. 2015;8(2):117-127.
Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528-540.

You are now leaving hattramyloidosis.co.uk

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from the site’s standards you are leaving.

Third Party Sites

Alnylam assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Alnylam or this website.

Thank you for visiting our site.

Cancel

The information on this site is intended for healthcare professionals and is not intended for the general public.

Sign up to receive updates about hereditary ATTR amyloidosis from Alnylam

I would like to speak with someone from the Alnylam Medical Affairs team about hereditary ATTR amyloidosis.

*Required Fields

By clicking submit, you certify that you are a healthcare professional.

Thank you

Your submission has been received.

Return to site

You are now leaving hATTR amyloidosis.com

Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.